Table 1a.

Rotavirus vaccine efficacy and effectiveness evaluations stratified by nutritional status, 2006–2020

Vaccine	Type of study	Year of publication	Country	Age group	Recruitment setting	Rotavirus endpoint	Indicator of malnutrition	Malnourished VE (95% CI)	Well-nourished VE (95% CI)	Reference
Rotarix	Randomized trial	2007	Brazil, Mexico, Venezuela	<12 months	Community	Rotavirus positive diarrhea	Weight-for-age	61 (10, 83)	61 (37, 75)	(27)
Rotarix	Case-control	2016	Botswana	4–59 months	Emergency department, inpatient	Rotavirus positive diarrhea	Weight-for-length	−28 (−309, 60)	75 (41, 89)	(28)
Rotarix	Case-control	2016	Malawi	<32 months	Emergency department, inpatient	Rotavirus positive diarrhea	Length-for-age	28 (−100, 74)	78 (6, 95)	(29)
Rotarix	Case-control	2019	Kenya	1–32 months	Inpatient	Rotavirus positive diarrhea	Weight-for-age	10 (−134, 66)	84 (62, 93)	(30)
							Length-for-age	28 (−118, 76)	75 (48, 88)
							Weight-for-length	−9 (−224, 63)	84 (64, 93)
Rotarix	Case-control	2019	Zimbabwe	6–11 months	Emergency department, inpatient	Rotavirus positive diarrhea	Length-for-age	45 (−148, 88)	71 (29, 88)	(31)
RotaTeq	Randomized trial	2017	Bangladesh, Vietnam	<24 months	Community	Rotavirus positive diarrhea	Weight-for-age	−3 (−256, 70)	45 (24, 60)	(32)
RotaTeq	Randomized trial	2017	Ghana, Kenya, Mali	<24 months	Community	Rotavirus positive diarrhea	Weight-for-age	21 (−34, 53)	32 (17, 43)	(32)
							Length-for-age	13 (−58, 52)	32 (18, 44)
							Weight-for-length	43 (15, 62)	26 (10, 40)